Parasitic Skin Disease
Research activity is centered on scabies, with attention to cases confirmed by clinical assessment and light microscopy. The therapeutic focus is on improving outcomes in a contagious ectoparasitic infestation that affects the skin and causes significant pruritus and discomfort.
- Scabies
- Clinical diagnosis
- Microscopy-confirmed infestation
The sponsor’s trial activity in this area is directed toward treatment effectiveness in routine dermatologic care.
Topical Antiparasitic Therapy
A key area of interest is topical permethrin 5%, reflecting involvement in treatment options for parasitic dermatoses. This includes evaluation of established topical therapy used to clear infestation and relieve skin symptoms.
- Permethrin 5%
- Topical treatment
- Dermatologic antiparasitic care
The research setting aligns with practical management of skin infestation in outpatient care.
Systemic Antiparasitic Treatment
The sponsor also funds research involving oral ivermectin, indicating interest in systemic antiparasitic therapy for scabies management. This domain covers treatment approaches that act beyond the skin surface and are used in clinical practice for infestation control.
- Ivermectin
- Oral therapy
- Systemic treatment
Clinical interest extends to the comparative use of oral and topical options in confirmed scabies.
Combination Treatment Strategies
Another therapeutic focus is the combined use of topical permethrin and oral ivermectin, highlighting interest in combination antiparasitic regimens for scabies. This area addresses treatment selection when a single approach may be insufficient.
- Combination therapy
- Dual antiparasitic regimen
- Short-term clinical cure
Research activity in this domain is focused on comparative therapeutic effectiveness in skin infestation management.
